Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study
Treatment strategies for MM outside Europe and North America align with guideline recommendations. More effective treatments and SCT at treatment initiation are needed. This study can guide future research in these regions utilizing newer treatment options.
Authors
- Su‐Peng Yeh (ORCID: https://orcid.org/0000-0001-6981-8677)
- Meral Beksaç (ORCID: https://orcid.org/0000-0002-4487-4004)
- Estelle Verburgh (ORCID: https://orcid.org/0000-0003-4657-7318)
- Wee Joo Chng (ORCID: https://orcid.org/0000-0003-2578-8335)
- Natalia Schütz (ORCID: https://orcid.org/0000-0002-1167-7186)
- Т. А. Митина (ORCID: https://orcid.org/0000-0001-7493-0030)
- Kihyun Kım (ORCID: https://orcid.org/0000-0002-5878-8895)
- Wen-Ming Chen (ORCID: https://orcid.org/0000-0001-9070-9280)
- Fahad Alsharif
- Zhongwen Huang
Institutions
- University of Cape Town (ZA)
- Capital Medical University (CN)
- China Medical University (TW)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- King Faisal Specialist Hospital & Research Centre (SA)
- Samsung Medical Center (KR)
- Groote Schuur Hospital (ZA)
- Hospital Italiano de Buenos Aires (AR)
- National University Cancer Institute, Singapore (SG)
- China Medical University Hospital (TW)
- Takeda (United States) (US)
- Regional Clinical Research (US)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- International Journal of Hematology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1007/s12185-025-03972-8
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Takeda Pharmaceuticals International